CSOP Hang Seng HK-US TECH ETF (03442.HK) Rises 0.48% to HK$8.345
New time space News, according to the latest data from the HKEX, as of 9:37 on May 6, the CSOP Hang Seng HK-US TECH ETF (03442.HK)gained 0.48% to trade at HK$8.345. The intraday high was HK$8.345and the low was HK$8.345, with an average price of HK$8.351. The total AUM stands at approximately HK$624million, with the latest Net Asset Value (NAV) per unit at HK$8.318, representing a premium of-0.01%.
The CSOP Hang Seng HK-US TECH ETF (03442.HK) tracks the Hang Seng HK-US Tech Index, an innovative cross-border technology-themed benchmark. It is designed to capture the performance of leading companies listed in Hong Kong whose business revenues are highly correlated with U.S. technology giants. By screening representative companies in the Hong Kong market across sectors such as electronics, semiconductors, software, and hardware, the index reflects the deep participation of the Chinese technology supply chain in the global ecosystem. It provides investors with an efficient tool to balance exposure to Hong Kong tech leaders while capturing the dividends of global (especially U.S. stock market) technological innovation.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
- NEW CENTURY GP(00234.HK): Indirect Non-wholly-owned Subsidiary Grants HK$8.7 Million Mortgage Loan to Wong Kwok Keung and Jiayuan Holdings at 12% Per Annum
- TAT HONG EQUIP(02153.HK): 10th Digital Securities Commercial Paper Issuance; Annual Interest Rate 4.40%, Planned Raising of SGD30 Million–35 Million